NYSE:BHVNBiotechs
How Biohaven’s (BHVN) Trade Secret Verdict Shapes Its Intellectual Property Defense Strategy
Earlier this week, Biohaven disclosed that a federal jury awarded the company US$1,000,000 in damages in a trade secret lawsuit against Avilar Therapeutics and RA Capital Management.
The verdict underscores the legal weight behind Biohaven’s efforts to safeguard its intellectual property, a core asset for any research‑driven biopharmaceutical business.
Next, we’ll examine how this courtroom win on intellectual property protection shapes Biohaven’s broader investment narrative over the coming...